Physician profile
Christopher Lawrence
NPI 1609984566
$1,664.87
in general payments reported to CMS, 2019-2025
19 companies · $648 in 2025
The $648 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.85 · 2020: $1.56 · 2021: $14.00 · 2022: $91.30 · 2023: $256 · 2024: $604 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,486 · Education: $22.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,486.06 |
| Education | $22.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $332.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.77 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $134.16 | 2022-2025 | Entyvio |
| Sandoz INC. | $128.93 | 2024-2025 | Hyrimoz |
| Ardelyx, INC. | $122.35 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $105.83 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Biotech, INC. | $97.50 | 2024-2025 | Tremfya, Stelara |
| Phathom Pharmaceuticals, INC. | $87.32 | 2024-2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $71.95 | 2023-2025 | Dupixent |
| Lilly USA, LLC | $64.83 | 2024-2025 | Omvoh |
| Genzyme Corporation | $58.35 | 2025 | |
| Braintree Laboratories, INC. | $49.89 | 2023-2024 | Sutab, Suflave |
| Aimmune Therapeutics, INC. | $37.40 | 2024-2025 | Zenpep |
| Ironwood Pharmaceuticals, INC | $36.86 | 2024 | |
| Exact Sciences Corporation | $31.67 | 2024 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $22.10 | 2024 | Zymfentra |
| Intercept Pharmaceuticals, INC. | $19.00 | 2024 | |
| Merck Sharp & Dohme LLC | $13.74 | 2024 | Dificid |
| Travere Therapeutics, INC. | $1.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lawrence listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.